Synthesis and
Characterization of (Diazenyl, Chalcone,
Pyrazole)-Derivatives
Shaimaa Adnan1*, Kasim Hassan2, Hassan Thamer3
1College of
Education, University of Al-Qadisiya, Iran
2College of Science, University of
Babylon, Iran
3College of
Education for Women- University of Kufa, Iran
*Corresponding Author
E-mail: shemia.adnan@yahoo.com
ABSTRACT:
In this study.,
heterocyclic compounds such as (isoxazolederivatives , pyrazol
derivatives, oxazepinederivatives), were prepared by reaction2-aminobenzaldehyde
with salicylaldehyde to get azo
compound (5-((1H-benzo[d]imidazol-2-yl)diazenyl)-2-hydroxybenzaldehyde)
(1),which react (in acid medium )
with 4-Bromoaniline to get
4-((1H-benzo[d]imidazol-2-yl)diazenyl)-2-(((4-bromophenyl)imino)methyl)phenol(2)
, and react with 4-aminobenzoicacid to get
1-(4-((5-((1H-benzo[d]imidazol-2-yl)diazenyl)-2-hydroxybenzylidene)amino)phenyl)ethanone(3)
(both shiff base) . in other side ,(1) react (
in base medium ) with 4-Bromoacetophenon to get
3-(5-((1H-benzo[d]imidazol-2-yl)diazenyl)-2-hydroxyphenyl)-1-(4-bromophenyl)prop-2-en-1-one(4)
,and react with 4-hydroxyacetophenone to get
3-(5-((1H-benzo[d]imidazol-2-yl)diazenyl)-2-hydroxyphenyl)-1-(4-hydroxyphenyl)prop-2-en-1-one(5)
(both chalcone derivatives).(2) and (3)react
with phthalic anhydride and maliec
anhydride to get
3-(5-((1H-benzo[d]imidazol-2-yl)diazenyl)-2-hydroxyphenyl)-4-(4-bromophenyl)-3,4-dihydrobenzo[e][1,3]oxazepine-1,5-dione(6),3-(5-((1H-benzo[d]imidazol-2-yl)diazenyl)-2-hydroxyphenyl)-4-(4-acetylphenyl)-3,4-dihydrobenzo[e][1,3]oxazepine-1,5-dione(7),
2-(5-((1H-benzo[d]imidazol-2-yl)diazenyl)-2-hydroxyphenyl)-3-(4-bromophenyl)-2,3-dihydro-1,3-oxazepine-4,7-dione(8),
2-(5-((1H-benzo[d]imidazol-2-yl)diazenyl)-2-hydroxyphenyl)-3-(4-acetylphenyl)-2,3-dihydro-1,3-oxazepine-4,7-dione(9).(oxazepine
derivatives) (4) and (5) react with hydrazinhydrate
to get 4-((1H-benzo[d]imidazol-2-yl)diazenyl)-2-(3-(4-bromophenyl)-4,5-dihydro-1H-pyrazol-5-yl)phenol(10),
4-((1H-benzo[d]imidazol-2-yl)diazenyl)-2-(3-(4-hydroxyphenyl)-4,5-dihydro-1H-pyrazol-5-yl)phenol(11),
and react with phenylhydrazine to get
4-((1H-benzo[d]imidazol-2-yl)diazenyl)-2-(5-(4-bromophenyl)-1-phenyl-2,3-dihydro-1H-pyrazol-3-yl)phenol(12),
4-((1H-benzo[d]imidazol-2-yl)diazenyl)-2-(5-(4-hydroxy
phenyl)-1-phenyl-2,3-dihydro-1H-pyrazol-3-yl)phenol(13) (pyrazol
derivatives). 4 and 5 react with hydroxylaminehydrochlorideto get
4-((1H-benzo[d]imidazol-2-yl)diazenyl)-2-(3-(4-bromophenyl)-2,5-dihydroisoxazol-5-yl)phenol(14),
4-((1H-benzo[d]imidazol
-2-yl)diazenyl)-2-(3-(4-hydroxyphenyl)-2,5-dihydroisoxazol-5-yl)phenol(15)
(isoxazolederivatives). All this
compounds characterized by means of FT- IR, and some of the compounds by means 1H-NMR,and 13C-NMRand
follow reaction by Rf- TLC andMeasurement melting point
.
KEYWORDS: Azomethine
,
Diazenyl , Anhydride , Dione.
INTRODUCTION:
Hetero aromatic compounds impart considerable attention in the
design of biologically active molecules and advanced organic materials(1-3).
The pyrazole ring is common in a number
of biologicallyactive molecules. More recently
extensive studies have been focused on pyrazole
derivatives forexhibiting analgesic,
anti-inflammatory, anticonvulsant, antidepressant, antiulcer, antidiabetic, cytotoxic, antitubercular and antibacterial. Antidepressants and
anticonvulsants are among the mostwidely utilized
drugs for the treatment of CNS disorders. Considerable interest has been
focused on thepyrazole structure, which has been
known to possess a broad spectrum of biological activities(4-9) .
Isoxazoles
are one of the five membered categorized heterocycle shaving two different hetero atoms in their
cyclic skeleton. In recent years there has been renewed interest in them due to
their uses as pharmaceutical1 and pesticide(10-12)
.
Oxazepine derivative is used as an antibiotic,
enzyme inhibitor, pharmacological interest, and has a biological activity. It
is used in relief of the psychoneuroses characterized by anxiety and tension (13-15).
Azo
ligands of heterocyclic compounds have received a special interest inbiological fields, due to the use some of these compounds
as biological stains . These compounds were under intese investigation and their activity as neoplastic and antibacterial agents worth extra attention(16-18)
.
Experimental Apparatus:
(FTIR) Spectra (4000-400cm-1)in KBr disk were recorded on a Shimadzu FTIR-8400S fourier transform. Melting point were
measured using Stuart, UK. 1HNMR and 13C-NMR were
recorded on fourier
transformation bruker spectrometer, operating at
(400MHz) with (DMSO-ds) measurements were made at
Department of Chemistry, Kashan University, Iran.
General method of synthesis of azo
compound (1)(19)
2-Amino-benzoimidazol
(0.005 m. mole, 0.665gm) of the aromatic amine was dissolved in 5 ml of
concentrated HCl and 8 ml of distilled water .The
mixture is cooled to 0C0 and (0.005m.mole, 0.345gm) of sodium
nitrite to added drop wise with continuous stirring. The solution was left for
15 minutes to be stable after completing the addition (0.005m.mole , 0.5 ml) of salicylaldehyde
dissolved in (1gmNaOH in 50ml H2O)was
added, a brown precipitate was formed, filtered and recrystallised
from methanol.
General
method of synthesis of schiff bases (2,3)(20)
A mixture of equimolar quantities (0.01mol) of compound (1) and benzenamine derivatives was refluxed for 20 min in 20 mL of
ethanol. The reaction mixture was cooled and kept for 24 h. The crystals found
was filtered and dried.
General
method of synthesis of Chalcone (4,5)(21)
Chalcone
was synthesized according to the hot condensation gms
(0.1 mole) derivatives acetophenone and (0.1 mole) compound(1) were dissolved in minimum amount of ethanol, 55
ml of 50% potassium hydroxide was added to the above solution. The flask was
heated at 50oC for twenty hours. The solution was acidified by cold
6 N HCl solution (Congored), crystalline solid separated, which was filtered
and washed with water. It was recrystallized from
ethanol.
General
method of synthesis of oxazepine (6,7,8,9)(22,23)
In a 100 ml
round bottom flask equipped with double surface condenser fitted with calcium
chloride guard tube was placed a mixture of 0.01 mole of shiff
base and0.01mole (maleic anhydride, phthalic anhydride) in 20 ml of Ethanol absolute. The
reaction mixture was refluxed in water bath at 78Cْ 3he, the
solvent was then removed and the resulting solid was recrystallized
from anhydrous THF.
General
method of synthesis of pyrazol (10,11,12,13)(24)
In a 100 ml
round bottom flask a mixture of 0.01 mole of Chalcone
and0.01mole (hydrazine hydrate, phenylhydrazine) in
50 ml of Ethanol absolute with continuous stirring at 72Cْfor 7 h, the solvent was then removed and the
resulting solid was recrystallized from ethanol.
General
method of synthesis of isoxazole (14,15)(25)
In a 100 ml
round bottom flask a mixture of 0.001 mole of Chalcone
and 0.001mole (hydroxylamine hydrochloride) in 50 ml of Ethanol absolute, after
that add 0.025mole from ammonium acetat with
continuous stirring at 72C ْfor
7 h, the solvent was then removed and the resulting solid was recrystallized from ethanol.
Results and Discussion:
Compound (1):
5-((1H-benzo[d]imidazol-2-yl)diazenyl)-2-hydroxybenzaldehyde
This compound
was obtained as Brown solid yield 41.6%, Rf
=0.6, M.P (186)OC.
The infrared spectrum data of compound (1) show absorption at (1735) cm-1 for (C=O),( 1458) cm-1 (-N=N-), (3409) cm-1 (OH) for phenol, and show band at (3139) for
(N-H)for imidazol and Disappearance band
for NH2 at (3379-3325) cm-1
The1H-NMR(DMSO)
spectrum data of compound (1) show
δ:6.3-7.3( m , 7H , Ar-H ) , 7.65 (m , 1H , NH )
,8.21 ( m , 1H,CH )Ald. , 10.59 (m, 1H,OH).
The13C-NMR(DMSO) spectrum data of compound (1) show δ:156.9 (C14), 138.3 (C11),
132.09(C1), 131.27(C9), 130.59(C6,C7), 126.46(C13), 124.19(C3,C4), 123.95(C8),
121.40(C12),113.03 (C10), 110.14 (C2,C5) .
Schem1:
Preparation of
compounds
Compound(2):4-((1H-benzo[d]imidazol-2-yl)diazenyl)-2-(((4-bromophenyl) imino) methyl) phenol
brown solid yield 80% , Rf =0.68 , M.P(
153)OC. The infrared spectrum data of compound (2) show absorption at (3016) cm-1 for (Ar-H),( 3348)
cm-1 (N-H),(594)cm-1 for(C-Br),(1626) cm-1 (C=N), and Disappearance band for (C=O) at
(1735)cm-1.
Compound(3):1-(4-((5-((1H-benzo[d]imidazol-2-yl)diazenyl)-2-hydroxybenzylidene)amino)phenyl)
ethanone was obtained as brown solid yield52.7%,Rf =0.8,M.P( 156)OC.
The infrared spectrum data of compound (3)show
absorption at (3031) cm-1
for (Ar-H),( 3332) cm-1
(N-H),(1635)cm-1 (C=N),and show band at (1481) for (-N=N-),(3394) cm-1
for (O-H ) and Disappearance band
for (C=O) at (1735)cm-1.
Compound(4):3-(5-((1H-benzo[d]imidazol-2-yl)diazenyl)
-2-hydroxyphenyl)-1-(4-bromophenyl)prop-2-en-1-one as brown solid, yield 32% ,Rf =0.65 , M.P( 197)OC.
The infrared spectrum data of compound (4) show absorption at,( 3178) cm-1 (N-H),( 1481)cm-1(N=N),and
show band at(1735)cm-1for (C=O), and(3031) cm-1 for (C-H) for Ar-H ,
(594)cm-1 for (C-Br),(3363) cm-1 (OH) for phenol.
The1H-NMR(DMSO)
spectrum data of compound (4) show
δ:7.2-7.8( m , 11H , Ar-H ) , 7.3 (m , 1H , NH )
,6.8 (m,2H,HC=CH), 8.21 .
Compound(5):3-(5-((1H-benzo[d]imidazol-2-yl)diazenyl)
-2-hydroxyphenyl)-1-(4-hydroxyphenyl)prop-2-en-1-one brownsolid, yield 58.8% ,Rf
=0.69 , M.P( 98d.)OC.
The infrared spectrum data of compound (5)show absorption at (1481)cm-1 for (N=N),(3124) cm-1
(N-H),(3031)cm-1(Ar-H),(1712) cm-1
for(C=O),and showband
at (1218) for (C-O),(3363) cm-1 (OH) for phenol.
Compound(6):3-(5-((1H-benzo[d]imidazol-2-yl)diazenyl)
-2-hydroxyphenyl)-4-(4-bromophenyl)-3,4-dihydrobenzo
[e][1,3]oxazepine-1,5-dione
Brown-yellow solid, yield 85% ,Rf =0.72 , M.P( 200)OC.
The infrared spectrum data of compound (6) show absorption at (3031) cm-1 for (Ar-H),(1630)cm-1(C=N),and
show band at (1481) for (N=N),(594) cm-1 for (C-Br), (1700) cm-1 for (C=O)
.
Compound(7):3-(5-((1H-benzo[d]imidazol-2-yl)diazenyl)
-2-hydroxyphenyl)-4-(4-acetylphenyl)-3,4-dihydrobenzo[e][1,3]oxazepine-1,5-dione as light golden solid, yield 91.5% ,Rf =0.81 , M.P( 175)OC.
The infrared spectrum data of compound (7) show absorption at (3039) cm-1 for (Ar-H),(1674)cm-1(C=N),and
show band at (1481) for (N=N),(1712) cm-1 for (C=O).
The1H-NMR(DMSO)
spectrum data of compound (7) show
δ:6.8-8( m , 11H , Ar-H ), 10.5 (s , 1H , NH ),
10.7 ( m , 1H,OH ), 8.2(s,1H,CH-N),1.32 (m,3H,CH3).
The13C-NMR(DMSO)
spectrum data of compound (7) show
δ:199 (C23), 170 (C15) 169.5(C16), 169(C11), 165.86(C17), 145.5(C1),
140.02(C20), 136.17(C6,C7), 133.49(C26), 133.34 (C27), 132.03 (C29,C30), 131.71
(C13,C12), 131.26(C19,C21), 131.21(C9,C28), 130.09 (C25), 129.39 (C3,C4),
121.97( C18), 120.32(C8), 112.92 (C16), 110.12(C2,C5).
Compound(8):2-(5-((1H-benzo[d]imidazol-2-yl)diazenyl)
-2-hydroxyphenyl)-3-(4-bromophenyl)-2,3-dihydro-1,3-oxazepine-4,7-dione as purple solid, yield 75.8% ,Rf
=0.7 , seram.
The infrared spectrum data of compound (8)show absorption at (1735)cm-1 for (C=O)oxazepin, (3132) cm-1 (N-H), (1650)cm-1(C=N),(3355)
cm-1 for (OH),and show band
at (594) for (C-Br)and show band at (1488) for (N=N).
The1H-NMR(DMSO)
spectrum data of compound (8) show
δ:6.07-7.49( m , 11H , Ar-H ), 10.58 (s , 1H ,
OH ), 4.1-3.6 ( m , 2H,CH=CH ),8.4(s,1H,CH-N),7.57 (m,1H,N-H) .
The13C-NMR(DMSO)
spectrum data of compound (1) show
δ:169 (C15), 165 (C18) 156.91(C11), 152.16(C1), 136.3(C19),
136.07(C20,C24), 133.44(C6,C7), 133.19(C16), 132.96(C21,C23), 132.22 (C13,C12),
131.23 (C9), 130.16(C4,C3), 124.59(C22), 123(C8), 122.02(C17), 112.93(C10),
110.14(C14).
Compound(9):2-(5-((1H-benzo[d]imidazol-2-yl)diazenyl)
-2-hydroxyphenyl)-3-(4-acetylphenyl)-2,3-dihydro-1,3-oxazepine-4,7-dione as brown, yield 92.8%, Rf
=0.8 , M.P (184) CO.
The infrared spectrum data of compound (8)show absorption at (1674)cm-1 for (C=O)oxazepin,(3271) cm-1 (N-H),(1630)cm-1(C=N),(3494)
cm-1 for(OH),and show band at
(1496) for (N=N).
The1H-NMR(DMSO)
spectrum data of compound (9) show
δ: 6-7.8( m,11H, Ar-H ), 8.3 (s , 1H , NH ),
4-4.3 (m,2HC=CH), 8.2(s,1H,CH-N), 3.1 (m, 6H,CH3) , 10.7 (m,1H,OH).
The13C-NMR(DMSO)
spectrum data of compound (9) show
δ:198.5 (C25), 169 (C15) 165.5(C18), 156.92(C11), 144.85(C19), 137.63(C1),
133.94(C22), 133.52(C6,C7), 132.34(C16,C17), 132.11 (C9,C23,C21,C13), 131.22
(C12), 131.04(C3,C4), 122.02(C20,C24), 120.27(C10), 110.17 (C2,C5), 30.61
(C14), 28.02( C26), 120.32(C8), 112.92(C16), 110.12(C2,C5).
Compound(10):4-((1H-benzo[d]imidazol-2-yl)diazenyl)-2-(3-(4-bromophenyl)-4,5-dihydro-1H-pyrazol-5-yl)phenol
as brown-yellowsolid,
yield 90% ,Rf =0.77 , M.P ( 268)OC.
The infrared spectrum data of compound (10) show absorption at (1689) cm-1 (C=N),and show new band at (3178) for (N-H) ,
(1481) cm-1 for(N=N) and
(3024)Cm-1 for (Ar-H), (594) Cm-1 for (C-Br), (3363)Cm-1
for (OH) phenol.
The1H-NMR(DMSO)
spectrum data of compound (10) show
δ:6.8-7.6( m , 11H , Ar-H ), 7.6 (s, 1H , NH),
10.5(m,1H,OH), 3.3(m,2H,CH2),4.09(m,1H,CH).
Compound(11):4-((1H-benzo[d]imidazol-2-yl)diazenyl)-2-(3-(4-hydroxyphenyl)-4,5-dihydro-1H-pyrazol-5-yl)
phenol as golden solid,
yield =69.5%, Rf =0.87 , M.P( 236)OC.
The infrared spectrum data of compound (11) show absorption at (1689) cm-1 (C=N), and show new band at (3132) for (N-H) ,
(1481) cm-1 for(N=N) and
(3024)Cm-1 for (Ar-H) , (3443)Cm-1 for (OH)phenol.
Compound(12):4-((1H-benzo[d]imidazol-2-yl)diazenyl)-2-(5-(4-bromophenyl)-1-phenyl-2,3-dihydro-1H-pyrazol-3-yl)phenolas
Brown solid, yield =36.4%
,Rf =0.7 , M.P(283)OC.
The infrared spectrum data of compound (12) show absorption, (3178) cm-1(N-H), (1481)cm-1 for (N=N), (3024)cm-1 for (Ar-H), (3363)cm-1
for (OH)
Compound(13):4-((1H-benzo[d]imidazol-2-yl)diazenyl)-2-(5-(4-hydroxyphenyl)-1-phenyl-2,3-dihydro-1H-pyrazol-3-yl)phenolas
Brown solid, yield =63.4% ,Rf =0.8, M.P(242)OC.
The infrared spectrum data of compound (12) show absorption,(3178) cm-1(N-H), (1481)
cm-1 for(N=N), (3024) cm-1 for (Ar-H), (3363)cm-1
for (OH)
The1H-NMR(DMSO) spectrum data of compound (11) show δ: 6.8-7.61(m, 16H, Ar-H), 7.8 (s, 1H, NH), 10.5(m, 2H, OH), 3.36(m, 2H, HC-CH).
Compound(14):4-((1H-benzo[d]imidazol-2-yl)diazenyl)-2-(3-(4-bromophenyl)-2,5-dihydroisoxazol-5-yl)phenol
as brown solid, yield =79.2% ,Rf =0.79 , seram.
The infrared spectrum data of compound (14) show absorption at (3024) cm-1 for (Ar-H),(3178) cm-1
(N-H),and show new band at ( 3533
)cm-1 for OH ,(594 )cm-1 for C-Br.
Compound(15):4-((1H-benzo[d]imidazol-2-yl)diazenyl)-2-(3-(4-hydroxyphenyl)-2,5-dihydroisoxazol-5-yl)phenol
as Brown solid, yield =87% ,Rf =0.6 , M.P(101)OC.
The infrared spectrum data of compound (14) show absorption at
(3024) cm-1 for (Ar-H), (3132) cm-1 (N-H), and show new band at ( 3533 ) cm-1 for OH .
The1H-NMR (DMSO)
spectrum data of compound (15) show δ: 6.8-7.4 (m, 11H, Ar-H), 7.7 (s, 1H, NH), 10.5 (m,1H,
OH), 3.36 (m,2H,HC-CH).
Table (1):- Analytical and physical data
of compounds.
No. |
Molecular formula |
Color |
M.P°C |
Yield% |
Rf |
1 |
C14H10N4O2 (266.25) |
Brown |
186 |
41.6 |
0.6 |
2 |
C20H14N5O
Br (420.26.219) |
Brown |
153 |
80 |
0.69 |
3 |
C22H17N5
O2 (383.403) |
Brown |
156 |
52.7 |
0.8 |
4 |
C22H15N4O2Br (447.284) |
Brown |
197 |
32 |
0.65 |
5 |
C22H16N4O3 (384.387) |
Brown |
98 d. |
58.8 |
0.59 |
6 |
C28H18N5O4Br (568.378) |
Brown-yellow |
200 |
85 |
0.72 |
7 |
C30H21N5O5 (338.42) |
Light golden |
175 |
91.5 |
0.81 |
8 |
C24H16N5O4Br (285.32) |
purple |
seram |
75.8 |
0.7 |
9 |
C26H19N5O5 (481.460) |
Brown |
184 |
92.8 |
0.8 |
10 |
C22H17N6O (460.065) |
Brown-yellow |
268 |
90 |
0.77 |
11 |
C22H18N6O2 (398.417) |
golden |
236 |
69.5 |
0.78 |
12 |
C28H21N6OBr (537.410) |
Brown |
283 |
36.4 |
0.7 |
13 |
C28H22N6O2 (474.513) |
Brown |
242 |
63.4 |
0.8 |
14 |
C22H16N5O2Br (462.299) |
Brown |
seram |
79.2 |
0.79 |
15 |
C22H17N5O3 (399.402) |
Brown |
101 |
87 |
0.6 |
REFERENCE:
1-
Ingle. R.G
and Magar. D.D ., J.S .India ,3 ,7, (2011).
2-
I.K. Jassim, S.S. Harth, R.M. Dhedan and A. Obais., Tkrit Pharmaceutical sciences, Iraq, 6, 3, 2012.
3-
E. Laxminarayayana, M.R. Kumar, D. Ramesh
and M.T. Chary., India, International
Journal of Chem Tech ,.2,.4, 2010.
4-
G.E. Delgado,
A.J. Mora, J.E. Contreras, J.B. Colmenarez and R. Atencio, Avancesen Quimica, 8(2),59-63(2013) .
5-
K. Li, Q. Feng and Z. Lea ., Actaceyst,66,02655 , 2010 .
6-
M. Wroblewske, J. Kasprzyk, F. Saczewski, A. Kornickg, K. Boblewski, A. Lehmann and
A. Rybczynska., Pharmacological Reporte, 1025-1032, 2013.
7-
A.J.A. Nasser,
A. Idayadhulla, R.S. Kumar and J. Selvin., J.Chem,7(4),1320-1325,
2010.
8-
N. Vale, J. Matos,
R. Moreira and P. Gomes., Tetrahedron J, 64,11144-11149 ,2008
9-
A. Catalano, A.
Carocci, G. Lentini ,A.D. Mola, C. Bruno and C. Franchini, J. of Heterocyclic Chemistry, 48,261,2011.
10-
S.P. Bajaj, O.A. Mahodaya and P.V. Tekada., Hetroletters J. :3(2),219-228 ,
2013.
11-
V. Tiwari, C. Ameta,
S. Sharma, M. Sharma, A.K. Pathak and P.B. Punjabi,Eur.Chem.Bull,2(5),242-246,2013 .
12-
V.D. Joshi, M.D. Kshirsagor and S. Singhal., J. Chem. Pharm.Res,2(6),3234-3238,
2012.
13-
Abood .Z.H., Iraq International Journal of Chemistry, (50), 207-246, 2013.
14-
Ibrahim .H.I., Baghdad Uni. J.
Education Collage, (62), 2010.
15-
Hameed .A., Journal of Al-Nahrain
University, 15(4) ,47-59,2012 .
16-
P.M. Savanor, K. Jatha
, R.S. Ali ,Der Chemica Sinica, 4(4), 49-54, 2013.
17-
H.F. Thamer, S.A. Dhahir,
S.A. Alsahib and I.A. Kattom,
J. Baghdad for Sci,
10(1),2013.
18-
B. Kirkan and R.Gup., Turk. J. Chem., 32,9-17,2008.
19-
H.A.S.A. Majeed, Journal of Basrah Researches Sciences,
38,.4, 2012.
20-
P. Selvam, P.P. Radhika,
S. Janagaraj, A.S. Kumar, Research Biotechnology, 2(3):50-57,2011.
21-
U. Sawarkar, M. Narule
and M. Chaudhary., Der Pharma Chemica., 4(2), 629-632, 2012.
22-
Nagham. M. Aljamali, M.
Jameel ,A.
A. Alhaidari, World.
J.P. Sci,1(4),163-167, 2013.
23-
Nagham. M. Aljamali., Int. Journal of Pharm and Pharmacology,. 3 (2), 149-153, 2014.
24-
Hanan. F. Tamimy, M.Sc. Thesis .Kufauni.2010
25-
Mehta. K.V., Inter J Chem Tech ,4(1) , 2012
.
Received on
10.02.2014 Modified on 20.03.2014
Accepted on
05.04.2014 ŠA&V Publications All right reserved
Research J.
Science and Tech. 6(2): April- June 2014; Page 95-100